

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P32147	SERIAL NO. 09/787,256
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Hayes, et al.	
		FILING DATE 3/15/01	GROUP 1625

U.S. PATENT DOCUMENTS


Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
BD	AA	5,633,262	5/27/97	Hong et al.	546	123	
BD	AB	5,776,944	7/7/98	Hong et al.	546	123	
BD	AC	5,869,670	2/9/99	Hong et al.	546	123	
BD	AD	5,962,468	10/5/99	Hong et al.	546	123	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BD	AE	G. Cormican, "Comparative Antimicrobial and Spectrum Activity of LB20304a, a New Fluorinated Naphthyridone Compound", <u>Abstracts of the 36th ICAAC</u> , 109 Abst F53 (1996)
BD	AF	J-H. Kwak, "Antimicrobial Activities of LB20304a, a New Quinolone Antibiotic", <u>The Journal of Applied Pharmacology</u> (4) pp. 378-384 (1996)
BD	AG	M-K. Seo, "Pharmacokinetics of LB20304, a New Fluoroquinolone, in Rats and Dogs", <u>Arch. Pharm. Res.</u> Vol. 19, No. 5, pp. 359-367 (1996)
BD	AH	C. Yong Hong, et al., "Novel Fluoroquinolone Antibacterial Agents Containing Oxime-Substituted (Aminomethyl) pyrrolidines: Synthesis and Antibacterial Activity of 7-(4-(Aminomethyl)-3-(methoxyimino) pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro [1,8] naphthyridine-3-carboxylic Acid (LB20304)", <u>J. Med. Chem.</u> 40 (22) pp. 3584-3593 (1997)
BD	AI	M-K. Seo et al., "High Performance Liquid Chromatographic Assay of a New Fluoroquinolone, LB20304, in the Plasma of Rats and Dogs", <u>Arch. Pharm. Res.</u> Vol. 19, No. 6, pp. 554-558 (1996)
BD	AJ	M-J. Ahn, et al., "In Vivo Efficacy of LB20304a against Experimental Respiratory Tract Infection in Mice", <u>Yakhak Hoeji</u> Vol. 40, No. 4, pp. 438-441 (1996)
EXAMINER B. Llent		DATE CONSIDERED 1/2/2002
EXAMINER: Initial if citation considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P32147	SERIAL NO. 09/787,256
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use several sheets if necessary)</i></p>		APPLICANT Hayes et al.	
		FILING DATE 3/15/01	GROUP 1625 1625

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]



Sheet of 1

TECH CENTER 1600/2900

AUG 20 2001

RECEIVED

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. P32147	SERIAL NO. 09/787,256
	APPLICANT Hayes, et al.	
	FILING DATE 3/15/01	GROUP XXXX

CO-PENDING PATENT APPLICATIONS

Examiner Initial	Attorney Docket No.	US Serial No.	Filing Date	Title	Inventors
BN	L50042X1	09/381,491	12/8/99	Salt of Naphthyridine Carboxylic Acid Derivative	Kim, et al.
BN	L50043	09/623,214	8/30/00	Process for Preparing a Protected 4- Aminomethyl-Pyrrolidin-3-One	Chang, et al.

EXAMINER <i>B. Denty</i>	DATE CONSIDERED <i>1-2-2002</i>
-----------------------------	------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.